The content you are about to view is intended exclusively
for healthcare professionals (including physicians, dentists, pharmacists, nurses and other licensed healthcare providers). Please confirm you are authorized to access information intended for healthcare professionals

MSB®Line is designed to compensate the butyric acid deficiency in the intestines by delivering butyrate in a proprietary MSB® form.

• MSB® is available in the form of capsules and sachets from 150 mg to 750 mg dosage in one portion of the product.

• Available dosages were clinically tested in various disorders.
   

• Clean label:
  products are vegan, free of gluten, lactose and other sugars, fibre, artificial dyes or flavours. Sachets contain natural fruit flavor (cranberry).

Proven beneficial nutritional effects in intestinal diseases and disorders in more than
3300* patients

IBD in children   

The benefit of the administration of MSB sodium butyrate in children
with inflammatory bowel diseases (L-C and UC). 

Study objectives: assessment of improvement in CRP, fecal calprotectin levels, and remission rate.
Duration: 12 weeks
Dosage: 1 x 150 mg of MSB®

Diverticular disease  

Microencapsulated sodium butyrate MSB® administered to patients with diverticulosis decreases the incidence of diverticulitis — a prospective randomized study.

Study objectives: assessment of recurrence rate of diverticulitis.
Duration: 12 months
Dosage: 2 x 150 mg of MSB®

T2D SIBO 

Effect of butyrate on gastrointestinal symptoms, and diabetes control—randomized,
placebo-controlled study in patients with type 2 diabetes and gastrointestinal disorders

Study objectives: assessment of change in metabolic parameters (HbA1c, BMI) and gastrointestinal disorders
(SIBO, abdominal pain, diarrhea, constipation, flatulence).
Duration: 12 weeks
Dosage: 2 x 750 mg of MSB®

IBS Study 3

The effectiveness of MSB® microencapsulated sodium butyrate at reducing symptoms
in patients with IBS. Assessment of the frequency of clinical
symptoms and quality of life in patients with IBS using MSB® in 3000 patients.

Study objectives: assessment of improvement in clinical symptoms and the quality of life of IBS patients.
Duration: 12 weeks
Dosage: 2 x 150 mg of MSB®

IBS Study 2

MSB® improves quality of life and reduces clinical symptoms in patients IBS.
Microencapsulated sodium butyrate MSB® reduces the incidence of abdominal painin patients with irritable bowel syndrome.

Study objectives: assessment of reduction in the severity of IBS symptoms and incidence of abdominal pain.
Duration: 12 weeks
Dosage: 2 x 150 mg of MSB®

IBS Study One

Outcome of treatment with butyric acid in IBS — a randomized, placebo-controlled study.

Study objectives: assessment of quality of life and severity of defecation.
Duration: 6 weeks
Dosage: 2 x 150 mg of MSB®

*The total number of patients participating in studies using MSB® was calculated on the basis of the following publications:

1. Krokowicz L. et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study. Two-centre, parallel, double blinded, randomized, placebo-controlled, per-protocol clinical: Int J Colorectal Dis Dec 2013

2. Tarnowski W et al.: Outcome of treatment with butyric acid in irritable bowel syndrome – preliminary report. Gastroenterologia Praktyczna 1/2011.

3. Krokowicz L., Kaczmarek BF., Krokowicz P. et al.: Sodium butyrate and short chain fatty acids in prevention of travellers’ diarrhoea: a randomized prospective study. Travel Medicine and Infectious Disease. 2014 Mar-Apr;12(2):183-8.

4. Banasiewicz T. et al.: Quality of life and clinical symptoms in patients with irritable bowel syndrome receiving complementary treatment with protected sodium butyrate. Gastroenterologia Praktyczna 5/2011.

5. Banasiewicz T. et al.: Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Disease 2012; The Association of Coloproctology of Great Britain and Ireland. 15,204-209

6. Lewandowski K. et al.: The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Przegląd Gastroenterologiczny2022;17(1):28-34.

7. Panufnik P. et al.: Effect of Butyrate on GI signs, SIBO, and Diabetes Control—Randomized, Placebo-Controlled Study in Patients with Type 2 Diabetes. Diabetes 2024;73(Supplement_1):610-P. 10.2337/db24-610-P

8. Goldiș A. et al.: Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory BowelDisease. Life (Basel). 2025 May 31;15(6):902. doi: 10.3390/life15060902. PMID: 40566555; PMCID: PMC12193763.

The Bioton S.A. Group has for years pursued a policy of manufacturing and introducing to the Polish and international markets effective and safe medicinal products, foods for special medical purposes, dietary supplements, and medical devices that meet global standards. Thanks to innovative production technologies and implemented quality assurance and control procedures, all products are manufactured under conditions that meet the quality requirements appropriate to each product category, including international Good Manufacturing Practice (GMP) requirements, as evidenced by continuously maintained quality certifications. Product quality and safety play a key role in the adopted quality policy, carried out by a highly specialized and competent team of experts. A high standard is ensured at every stage—from development, through manufacturing and storage, to distribution. At the same time, through ongoing monitoring and continuous improvement of quality initiatives, the implemented Quality System is maintained, ensuring adherence to the highest quality standards.

info@biolek.com.pl